收藏切换
Bioequivalence study of haloperidol in healthy Chinese subjects
收藏切换
PDF
Chun-chun FANG1, Feng-jie LIANG1, Hui-hui SONG1, You-hong SHEN1, Yu-sheng HE2, Xiao-fen LOU1
Chinese Journal of Clinical Pharmacology | 2025, 41(8) : 1152 - 1156
Less
收藏切换
Chinese Journal of Clinical Pharmacology | 2025, 41(8): 1152-1156
Pharmacokinetics and Bioequivalence Study
Bioequivalence study of haloperidol in healthy Chinese subjects
Full
Chun-chun FANG1, Feng-jie LIANG1, Hui-hui SONG1, You-hong SHEN1, Yu-sheng HE2, Xiao-fen LOU1
Affiliations
  • 1.Ningbo Dahongying Pharmaceutical Co., Ltd., Ningbo 315822, Zhejiang Province, China
  • 2.Drug Clinical Trial Institution, People’s Hospital Affiliated to Chongqing Three Gorges Medical College, Chongqing 404199, China
Published: 2025-04-28 doi: 10.13699/j.cnki.1001-6821.2025.08.018
Outline
收藏切换
Objective

To study the bioequivalence of two formulations of haloperidol tablets in healthy Chinese subjects.

Methods

The randomized, open, single dose, two periods, crossover study design was adopted in the study. Twenty-eight healthy subjects were enrolled under fasting condition and given either test preparation or reference preparation 2 mg respectively in one period. After collecting plasma samples, the plasma concentrations of haloperidol were determined by liquid chromatography-tandem mass spectrometry (LC-MS/MS). The pharmacokinetic parameters were calculated by WinNonlin 8.0 and the bioequivalence was evaluated using the average bioequivalence (ABE) method.

Results

The pharmacokinetic parameters of haloperidol of the test preparation or reference preparation were as follow: Cmax were (719.50±378.43) and (703.43±329.63) pg·mL-1, AUC0-t were (1.94×104±6 766.21) and (1.94×104±6 522.79) pg·h·mL-1, AUC0-∞ were (2.31×104±7 693.66) and (2.30×104±7 309.97) pg·h·mL-1. The 90% confidence intervals (CI) of the geometric mean ratio (GMR) were 92.46%-114.76%, 96.70%-108.15%, 96.36%-111.34% for Cmax, AUC0-t and AUC0-∞, respectively, which were within the acceptance criteria of 80.00%-125.00%.

Conclusion

The two preparations of haloperidol tablets were bioequivalent in Chinese healthy subjects.

haloperidol tablet  /  pharmacokinetics  /  bioequivalence
Chun-chun FANG, Feng-jie LIANG, Hui-hui SONG, You-hong SHEN, Yu-sheng HE, Xiao-fen LOU. Bioequivalence study of haloperidol in healthy Chinese subjects[J]. Chinese Journal of Clinical Pharmacology, 2025 , 41 (8) : 1152 -1156 . DOI: 10.13699/j.cnki.1001-6821.2025.08.018
Year 2025 volume 41 Issue 8
PDF
1
0
Cite this Article
BibTeX
Article Info
doi: 10.13699/j.cnki.1001-6821.2025.08.018
  • Receive Date:2024-12-28
  • Online Date:2026-08-04
  • Published:2025-04-28
Article Data
Affiliations
History
  • Received:2024-12-28
Affiliations
    1.Ningbo Dahongying Pharmaceutical Co., Ltd., Ningbo 315822, Zhejiang Province, China
    2.Drug Clinical Trial Institution, People’s Hospital Affiliated to Chongqing Three Gorges Medical College, Chongqing 404199, China
References
Share
https://castjournals.cast.org.cn/joweb/zglcylxzz/EN/10.13699/j.cnki.1001-6821.2025.08.018
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数

Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)

Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT